16 May 2016
Syndax Pharmaceuticals (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today reported its financial results for the first quarter ended March 31, 2016, and provided a pipeline update and review of upcoming milestones. As of March 31, 2016, Syndax had $133.7 million in cash, cash equivalents and short-term investments.
Good long-term visual acuities reported in presbyopic patients implanted with Raindrop inlay
13 May 2016
Good long-term visual acuities for distance and near were achieved in presbyopic patients, both emmetropic and hyperopic, implanted with the ReVision Optics Raindrop inlay, according to a study presented by Cornelis Verdoorn, MD, at the American Society of Cataract and Refractive Surgery meeting here.
Clearside Biomedical Announces Potential Pricing for IPO
13 May 2016
Clearside Biomedical has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 4 million shares in the range of $14 to $16 per share, with an overallotment option for an additional 600,000 shares. At the maximum price the entire offering is valued up to $73.6 million. The company intends to list its shares on the Nasdaq Global Market under the symbol CLSD.
03 May 2016
Celtaxsys, a clinical stage drug development company focused on advancing therapies for patients with rare and orphan inflammatory diseases, announced today the opening of enrollment in Europe of an international phase 2 clinical trial for acebilustat, its flagship treatment for people with cystic fibrosis (CF).
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
02 May 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended March 31, 2016.
26 April 2016
Ñlearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.
19 April 2016
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data of ganaxolone IV, the Company’s intravenous formulation of its CNS-selective GABAA modulator, showing robust activity in a well-accepted and clinically translatable animal model of status epilepticus (SE). The data were presented during an oral and poster presentations at the 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.
15 April 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the intravenous (IV) formulation of its CNS-selective GABAAmodulator, ganaxolone, for the treatment of status epilepticus. A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016.
Atlas Genetics wins SBRI grant from Innovate UK
15 March 2016
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded an SBRI grant from Innovate UK to assist in the development of an ultra-rapid POC multiplex STI test measuring the four most commonly occurring pathogens (Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis and Mycoplasma genitalium) in less than 30 minutes.
09 March 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that results from its ongoing Phase III U.S. FDA clinical study evaluating the Raindrop Near Vision Inlay for the treatment of presbyopia show significantly improved near visual performance and produced a 92% rate of satisfaction among study subjects one year following the procedure. T
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024
CRISPR technologies fuelling haematological innovations
17 April 2024
17 April 2024